Welcome to Paid Research Studies




  • Condition:   Frontotemporal Dementia
    Intervention:   Drug: Syntocinon
    Sponsors:   Lawson Health Research Institute;   Weston Brain Institute;   Canadian Institutes of Health Research (CIHR);   Berry Consultants
    Recruiting

  • Condition:   Familial Frontotemporal Dementia
    Intervention:  
    Sponsors:   Mayo Clinic;   National Institute on Aging (NIA);   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting

  • Conditions:   Healthy;   Frontotemporal Dementia
    Interventions:   Biological: AL001;   Other: Placebo
    Sponsor:   Alector Inc.
    Recruiting

  • Condition:   Primary Progressive Aphasia
    Intervention:   Behavioral: Evidence-Based Treatment
    Sponsors:   Northwestern University;   National Institute on Aging (NIA)
    Recruiting

  • Condition:   Primary Progressive Aphasia
    Intervention:  
    Sponsors:   Northwestern University;   National Institute on Deafness and Other Communication Disorders (NIDCD)
    Recruiting

  • Condition:   Primary Progressive Aphasia
    Intervention:   Device: Transcranial Magnetic Stimulation
    Sponsors:   Hospital San Carlos, Madrid;   Universidad Complutense de Madrid
    Recruiting

  • Condition:   Semantic Dementia
    Intervention:   Device: Transcranial stimulation
    Sponsor:   Assistance Publique - Hôpitaux de Paris
    Not yet recruiting

  • Condition:   Niemann-Pick Diseases
    Intervention:  
    Sponsor:   Centogene AG Rostock
    Recruiting

  • Conditions:   Primary Progressive Aphasia;   PPA
    Interventions:   Device: Active tDCS plus Speech-Language Therapy;   Device: Sham tDCS plus Speech-Language Therapy
    Sponsor:   Johns Hopkins University
    Recruiting

  • Condition:   Niemann-Pick Disease, Type C
    Intervention:   Drug: 2-Hydroxypropyl-Beta-Cyclodextrin
    Sponsors:   Washington University School of Medicine;   Johns Hopkins University;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Condition:   Frontotemporal Dementia
    Intervention:   Radiation: (18F)-FEPPA
    Sponsor:   Lawson Health Research Institute
    Recruiting

  • Condition:   Neimann-Pick Disease, Type C
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Conditions:   Primary Progressive Aphasia;   MCI;   FTD
    Interventions:   Device: Active tDCS plus Speech-Language Therapy;   Device: Sham plus Speech-Language Therapy
    Sponsors:   Johns Hopkins University;   National Institutes of Health (NIH);   National Institute on Deafness and Other Communication Disorders (NIDCD)
    Recruiting

  • Condition:   Primary Progressive Aphasia
    Interventions:   Device: HD-tDCS;   Device: Sham
    Sponsor:   Medical College of Wisconsin
    Not yet recruiting

  • Condition:   Primary Progressive Aphasia
    Intervention:   Device: transcranial direct current stimulation
    Sponsor:   University of Pennsylvania
    Recruiting

  • Conditions:   Frontotemporal Dementia;   GRN Related Frontotemporal Dementia
    Interventions:   Device: Anodal transcranial direct current stimulation;   Device: Sham transcranial direct current stimulation
    Sponsor:   Azienda Ospedaliera Spedali Civili di Brescia
    Recruiting

  • Conditions:   Frontotemporal Lobar Degeneration;   Amytrophic Lateral Sclerosis;   Progressive Supranuclear Palsy
    Intervention:  
    Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting

  • Condition:   Niemann-Pick Disease, Type C
    Intervention:   Drug: IB1001
    Sponsor:   IntraBio Inc
    Not yet recruiting

  • Conditions:   Logopenic Variant Primary Progressive Aphasia;   Non-Fluent Primary Progressive Aphasia
    Interventions:   Device: Active rTMS;   Device: SHAM rTMS
    Sponsors:   Brigham and Women's Hospital;   Massachusetts General Hospital
    Recruiting

  • Condition:   Niemann-Pick Disease, Type C1
    Intervention:   Drug: Hydroxypropyl-beta-cyclodextrin
    Sponsor:   CTD Holdings, Inc.
    Recruiting

  • Condition:   Niemann-Pick Disease, Type C1
    Intervention:   Drug: Hydroxypropyl-beta-cyclodextrin
    Sponsor:   CTD Holdings, Inc.
    Recruiting

  • Conditions:   Niemann-Pick Disease;   Niemann-Pick Disease, Type C
    Intervention:  
    Sponsor:   Centogene AG Rostock
    Recruiting

  • Condition:   Primary Progressive Nonfluent Aphasia
    Interventions:   Device: Active iTBS;   Device: Sham iTBS
    Sponsor:   University of British Columbia
    Not yet recruiting

  • Condition:   Niemann-Pick Disease, Type C
    Intervention:   Drug: VTS-270
    Sponsor:   Vtesse, Inc., a Mallinckrodt Pharmaceuticals Company
    Not yet recruiting

  • Condition:   Niemann-Pick Disease, Type C1
    Intervention:   Drug: Lithium Carbonate
    Sponsor:   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
    Recruiting

  • Condition:   Niemann-Pick Disease, Type C
    Intervention:   Drug: VTS-270
    Sponsor:   Vtesse, Inc., a Mallinckrodt Pharmaceuticals Company
    Not yet recruiting

  • Condition:   Primary Progressive Aphasia With Suspected Alzheimer's Disease
    Interventions:   Drug: 18F-AV-1451;   Device: PET
    Sponsors:   Northwestern University;   National Institute on Aging (NIA)
    Recruiting

  • Conditions:   Dementia;   Alzheimer's Disease;   Frontotemporal Dementia
    Interventions:   Device: In-home technology;   Device: Limited in-home technology
    Sponsors:   University of California, Berkeley;   University of California, San Francisco;   People Power Company;   National Institute on Aging (NIA)
    Not yet recruiting

  • Conditions:   Alzheimer Disease;   Alzheimer Dementia;   Frontotemporal Dementia
    Interventions:   Device: Spectral-Domain Optical Coherence Tomography (SD-OCT);   Device: Magnetic Resonance Imaging (MRI);   Device: Positron Emission Tomography (PET);   Diagnostic Test: Comprehensive Ophthalmic Examination;   Device: Fundus Photography
    Sponsor:   University of Michigan
    Recruiting

  • Conditions:   Amyotrophic Lateral Sclerosis (ALS);   Familial Amyotrophic Lateral Sclerosis;   Amyotrophic Lateral Sclerosis With Frontotemporal Dementia;   Lou Gehrig's Disease;   Motor Neuron Disease;   Primary Lateral Sclerosis
    Intervention:   Other: Genetic study of ALS families
    Sponsor:   Northwestern University
    Recruiting

  • Conditions:   Progressive Supranuclear Palsy (PSP);   Corticobasal Degeneration (CBD);   Frontotemporal Dementia (FTD MAPT Mutation)
    Intervention:   Other: 13C6 Leucine
    Sponsors:   Washington University School of Medicine;   Association of Frontotemporal Degeneration;   Tau Consortium
    Recruiting

  • Conditions:   Apathy;   Frontotemporal Dementia;   Parkinson Disease;   Depressive Symptoms
    Interventions:   Behavioral: ECOCAPTURE;   Behavioral: Cognitive and Behavioral experimental tasks;   Diagnostic Test: Neuropsychological assessment;   Behavioral: ICM_APATHY_TASKS;   Other: MRI;   Biological: Neurohormonal mechanisms;   Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's Disease
    Sponsor:   Institut National de la Santé Et de la Recherche Médicale, France
    Recruiting

  • Conditions:   Healthy Volunteer;   Alzheimer Disease;   Frontotemporal Dementia;   Parkinson Disease
    Intervention:   Drug: [18F]PI-2620
    Sponsors:   Asan Medical Center;   Korea Health Industry Development Institute
    Recruiting

  • Conditions:   Amyotrophic Lateral Sclerosis;   ALS-Frontotemporal Dementia;   Primary Lateral Sclerosis;   Progressive Muscular Atrophy
    Intervention:  
    Sponsors:   University of Miami;   Muscular Dystrophy Association;   National Institute of Neurological Disorders and Stroke (NINDS);   National Center for Advancing Translational Science (NCATS);   National Institutes of Health (NIH)
    Recruiting

  • Conditions:   Aphasia, Primary Progressive;   Anomia;   Alzheimer Disease
    Interventions:   Behavioral: Phonological;   Behavioral: Orthographic;   Behavioral: Semantic;   Behavioral: Lexical;   Behavioral: Untrained
    Sponsors:   Georgetown University;   National Institute on Deafness and Other Communication Disorders (NIDCD);   National Institute on Aging (NIA);   Johns Hopkins University
    Recruiting

  • Conditions:   Corticobasal Syndrome;   Progressive Supranuclear Palsy;   Behavioral Variant Frontotemporal Dementia;   Semantic Dementia;   Progressive Nonfluent Aphasia;   Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia
    Intervention:   Other: Observational Study
    Sponsor:   University Health Network, Toronto
    Recruiting

  • Conditions:   Apraxia of Speech;   Non-fluent Aphasia;   Primary Progressive Aphasia;   Primary Progressive Nonfluent Aphasia
    Intervention:   Diagnostic Test: Testing protocol for the study
    Sponsor:   Mayo Clinic
    Recruiting

  • Conditions:   FTLD;   Progressive Supranuclear Palsy (PSP);   Frontotemporal Dementia (FTD);   Corticobasal Degeneration (CBD);   PPA Syndrome;   Behavioral Variant Frontotemporal Dementia (bvFTD);   Semantic Variant Primary Progressive Aphasia (svPPA);   Nonfluent Variant Primary Progressive Aphasia (nfvPPA);   FTD With Amyotrophic Lateral Sclerosis (FTD/ALS);   Amyotrophic Lateral Sclerosis (ALS);   Oligosymptomatic PSP (oPSP);   Corticobasal Syndrome (CBS)
    Intervention:  
    Sponsors:   University of California, San Francisco;   National Center for Advancing Translational Science (NCATS);   National Institute of Neurological Disorders and Stroke (NINDS);   The Bluefield Project;   Tau Consortium
    Recruiting

  • Conditions:   Amyotrophic Lateral Sclerosis;   Frontotemporal Dementia;   Primary Lateral Sclerosis;   Hereditary Spastic Paraplegia;   Progressive Muscular Atrophy;   Multisystem Proteinopathy
    Intervention:  
    Sponsors:   University of Miami;   National Institute of Neurological Disorders and Stroke (NINDS);   National Center for Advancing Translational Science (NCATS);   St. Jude Children's Research Hospital;   ALS Association
    Recruiting

  • Conditions:   PPA;   Non-fluent Aphasia;   Apraxia of Speech;   Primary Progressive Non-fluent Aphasia;   Primary Progressive Aphasia
    Intervention:   Drug: AV-1451
    Sponsor:   Mayo Clinic
    Recruiting

  • Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;   Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;   Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;   Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;   Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia - Renal Agenesis - Psychomotor Retardation;   Aniridia - Ptosis - Intellectual Disability - Familial Obesity;   Aniridia - Cerebellar Ataxia - Intellectual Disability;   Aniridia - Absent Patella;   Aniridia;   Peters Anomaly - Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability - Ataxia - Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia - Unknown;   Spinocerebellar Ataxia - Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spectrin-associated Autosomal Recessive Cerebellar Ataxia;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia - Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia - Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;   Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;   Non-progressive Cerebellar Ataxia With Intellectual Disability;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy - Deafness;   NARP Syndrome;   Myoclonus - Cerebellar Ataxia - Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Lethal Ataxia With Deafness and Optic Atrophy;   Leigh Syndrome;   Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;   Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;   Leigh Syndrome With Nephrotic Syndrome;   Leigh Syndrome With Leukodystrophy;   Leigh Syndrome With Cardiomyopathy;   Late-onset Ataxia With Dementia;   Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;   Infection or Post Infection Ataxia;   Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;   Infantile Onset Spinocerebellar Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract - Ataxia - Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia - Hypogonadism;   Cerebellar Ataxia - Ectodermal Dysplasia;   Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly - Nystagmus - Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;   Ataxia-deafness-intellectual Disability Syndrome;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia Neuropathy Spectrum;   Ataxia - Tapetoretinal Degeneration;   Ataxia - Photosensitivity - Short Stature;   Ataxia - Pancytopenia;   Ataxia - Oculomotor Apraxia Type 1;   Ataxia - Hypogonadism - Choroidal Dystrophy;   Ataxia - Other;   Ataxia - Genetic Diagnosis - Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia;   Multiple Endocrine Neoplasia;   Multiple Endocrine Neoplasia Type II;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Multiple Endocrine Neoplasia, Type IV;   Multiple Endocrine Neoplasia, Type 3;   Multiple Endocrine Neoplasia (MEN) Syndrome;   Multiple Endocrine Neoplasia Type 2B;   Multiple Endocrine Neoplasia Type 2A;   Atypical Hemolytic Uremic Syndrome;   Atypical HUS;   Wiedemann-Steiner Syndrome;   Breast Implant-Associated Anaplastic Large Cell Lymphoma;   Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA);   Hemophagocytic Lymphohistiocytosis;   Behcet's Disease;   Alagille Syndrome;   Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD);   Lowe Syndrome;   Pitt Hopkins Syndrome;   1p36 Deletion Syndrome;   Jansen Type Metaphyseal Chondrodysplasia;   Cockayne Syndrome;   Chronic Recurrent Multifocal Osteomyelitis;   CRMO;   Malan Syndrome;   Hereditary Sensory and Autonomic Neuropathy Type Ie
    Intervention:  
    Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group;   Mucolipidosis Type IV (ML4) Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated;   American Multiple Endocrine Neoplasia Support;   Atypical Hemolytic Uremic Syndrome Foundation;   All Things Kabuki;   Wiedemann-Steiner Syndrome Foundation;   Breast Implant Victim Advocates;   PROS Foundation;   American Behcet's Disease Association
    Recruiting

  • Conditions:   Dementia;   Alzheimer Disease;   Circadian Rhythm Disorders;   Circadian Rhythm Sleep Disorder;   Insomnia;   Hypersomnia;   Cognitive Impairment;   Cognitive Decline;   Mild Cognitive Impairment;   Frontotemporal Dementia;   Neurocognitive Disorders;   Vascular Dementia;   Sleep Disorder;   Memory Impairment
    Interventions:   Behavioral: Attention-Control Condition;   Behavioral: Timed Activity Intervention
    Sponsor:   University of Pennsylvania
    Recruiting

  • Conditions:   Amyotrophic Lateral Sclerosis;   Frontotemporal Dementia;   PLS;   Motor Neuron Disease;   Lou Gehrigs Disease;   Familial Disease;   Amyotrophic Lateral Sclerosis, Sporadic;   Muscular Dystrophy;   Miyoshi Myopathy
    Intervention:  
    Sponsors:   University of Massachusetts, Worcester;   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting

  • Conditions:   Corticobasal Degeneration (CBD);   Corticobasal Syndrome (CBS);   Cortical-basal Ganglionic Degeneration (CBGD);   Progressive Supranuclear Palsy (PSP);   Nonfluent Variant Primary Progressive Aphasia (nfvPPA);   Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)
    Intervention:   Other: Observational Study
    Sponsors:   University of California, San Francisco;   National Institutes of Health (NIH);   National Institute on Aging (NIA)
    Recruiting

  • Conditions:   MLD;   Krabbe Disease;   ALD;   MPS I;   MPS II;   MPS III;   Vanishing White Matter Disease;   GM3 Gangliosidosis;   PKAN;   Tay-Sachs Disease;   NP Deficiency;   Osteopetrosis;   Alpha-Mannosidosis;   Sandhoff Disease;   Niemann-Pick Diseases;   MPS IV;   Gaucher Disease;   GAN;   GM1 Gangliosidoses;   Morquio Disease;   S-Adenosylhomocysteine Hydrolase Deficiency;   Batten Disease;   Pelizaeus-Merzbacher Disease;   Leukodystrophy;   Lysosomal Storage Diseases;   Purine Nucleoside Phosphorylase Deficiency;   Multiple Sulfatase Deficiency Disease
    Interventions:   Other: Palliative Care;   Biological: Hematopoetic Stem Cell Transplantation
    Sponsor:   University of Pittsburgh
    Recruiting

  • Conditions:   Adrenoleukodystrophy;   Batten Disease;   Mucopolysaccharidosis II;   Leukodystrophy, Globoid Cell;   Leukodystrophy, Metachromatic;   Neimann Pick Disease;   Pelizaeus-Merzbacher Disease;   Sandhoff Disease;   Tay-Sachs Disease;   Brain Diseases, Metabolic, Inborn;   Alpha-Mannosidosis;   Sanfilippo Mucopolysaccharidoses
    Intervention:   Biological: DUOC-01
    Sponsors:   Joanne Kurtzberg, MD;   The Marcus Foundation
    Recruiting

  • Conditions:   Ataxia;   Dystonia;   Parkinson's Disease;   Amyotrophic Lateral Sclerosis;   Corticobasal Degeneration;   Multiple System Atrophy;   Alzheimer's Disease;   Lewy Body Dementia;   Parkinson Disease-Dementia;   Dentatorubral-pallidoluysian Atrophy;   Creutzfeldt-Jakob Disease and Fatal Familial Insomnia;   Fragile X-associated Tremor/Ataxia Syndrome;   Krabbe's Disease;   Niemann-Pick Disease, Type C;   Neuronal Ceroid Lipofuscinosis
    Intervention:  
    Sponsor:   National Institute on Aging (NIA)
    Recruiting

  • Conditions:   Dementia;   Alzheimer Disease;   Parkinson Disease;   Lewy Body Disease;   Parkinson-Dementia Syndrome;   Frontotemporal Degeneration;   Semantic Dementia;   Progressive Nonfluent Aphasia;   Progressive Supranuclear Palsy;   Corticobasal Degeneration;   Multiple System Atrophy;   Mild Cognitive Impairment
    Interventions:   Diagnostic Test: Flutemetamol F18 Injection;   Diagnostic Test: [18F]-RO6958948;   Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;   Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau
    Sponsors:   Skane University Hospital;   Lund University
    Recruiting

  • Conditions:   Alzheimer Disease, Early Onset;   Alzheimer Disease;   Alzheimer Disease, Late Onset;   Dementia, Alzheimer Type;   Logopenic Progressive Aphasia;   Primary Progressive Aphasia;   Visuospatial/Perceptual Abilities;   Posterior Cortical Atrophy;   Executive Dysfunction;   Corticobasal Degeneration;   Ideomotor Apraxia
    Intervention:  
    Sponsors:   University of California, Los Angeles;   National Institute on Aging (NIA);   University of Southern California
    Recruiting

  • Condition:   Niemann-Pick Type C Disease
    Intervention:   Drug: VTS270
    Sponsor:   Vtesse, Inc., a Mallinckrodt Pharmaceuticals Company
    Available

  • Conditions:   Alzheimer Disease;   Dementia;   Mild Cognitive Impairment;   Aging;   Aging Disorder
    Intervention:  
    Sponsor:   Georgetown University
    Recruiting

  • Conditions:   Primary Tauopathies;   Corticobasal Degeneration Syndrome;   Frontotemporal Lobar Degeneration With Tau Inclusions;   MAPT Mutation Carriers, Symptomatic;   Traumatic Encephalopathy Syndrome;   Nonfluent Aphasia, Progressive
    Interventions:   Drug: BIIB092;   Other: Placebo
    Sponsor:   University of California, San Francisco
    Recruiting

  • Condition:   Lysosomal Storage Disorders
    Intervention:  
    Sponsor:   O & O Alpan LLC
    Recruiting

  • Condition:   Dementia-related Psychosis
    Interventions:   Drug: Placebo;   Drug: Pimavanserin 34 mg;   Drug: Pimavanserin 20 mg
    Sponsor:   ACADIA Pharmaceuticals Inc.
    Recruiting